FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Shani Eli 2. Date of Event Requiring Statement (MM/DD/YYYY)
8/15/2021 

3. Issuer Name and Ticker or Trading Symbol TEVA PHARMACEUTICAL INDUSTRIES LTD [TEVA]
(Last)       (First)       (Middle)
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP,Global Marketing&Portfolio /
(Street)
TEL AVIV, L3 6944020      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares (1) 9091  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Share Units   (2)  (2) Ordinary Shares (1) 6346   (3) D   
Restricted Share Units   (4)  (4) Ordinary Shares (1) 1581   (3) D   
Restricted Share Units   (5)  (5) Ordinary Shares (1) 23586   (3) D   
Restricted Share Units   (6)  (6) Ordinary Shares (1) 15934   (3) D   
Stock Options (right to buy)   (7) 8/10/2028  Ordinary Shares (1) 16503  $22.48  D   
Stock Options (right to buy)   (8) 3/3/2027  Ordinary Shares (1) 13002  $34.70  D   
Stock Options (right to buy)   (9) 3/17/2026  Ordinary Shares (1) 13005  $53.50  D   
Stock Options (right to buy)   (10) 3/12/2025  Ordinary Shares (1) 14252  $60.21  D   
Stock Options (right to buy)   (11) 3/12/2024  Ordinary Shares (1) 15002  $48.76  D   
Stock Options (right to buy)   (12) 2/24/2023  Ordinary Shares (1) 4170  $38.08  D   
Stock Options (right to buy)   (13) 2/24/2022  Ordinary Shares (1) 2669  $44.59  D   

Explanation of Responses:
(1)  The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
(2)  Restricted share units were granted on March 4, 2019, with 3,173 vesting on each of March 4 2022 and March 4, 2023.
(3)  Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
(4)  Restricted share units were granted on August 10, 2018, with 1,581 vesting on August 10, 2022.
(5)  Restricted share units were granted on March 5, 2021, with 5,896 vesting on each of March 5, 2022, March 5, 2023 and March 5, 2024 and 5,898 vesting on March 5, 2025.
(6)  Restricted share units were granted on February 28, 2020, with 5,311 vesting on each of February 28, 2022 and February 28, 2023 and 5,312 vesting on February 28, 2024.
(7)  Stock options were granted on August 10, 2018, with 4,152 vesting on each of August 10, 2019, August 10, 2020 and August 10, 2021 and 4,128 vesting on August 10, 2022.
(8)  Stock options were granted on March 3, 2017, with 3,250 vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 3,252 vested on March 3, 2021.
(9)  Stock options were granted on March 17, 2016, with 3,251 vested on each of March 17, 2017, March 17, 2018 and March 17, 2019 and 3,252 vested on March 17, 2020.
(10)  Stock options were granted on March 12, 2015, with 3,563 vested on each of March 12, 2016, March 12, 2017, March 12, 2018 and March 12, 2019.
(11)  Stock options were granted on March 12, 2014, with 5,000 vested on each of March 12, 2015 and March 12, 2016 and 5,002 vested on March 12, 2017.
(12)  Stock options were granted on February 24, 2013, with 4,170 having vested on February 24, 2016.
(13)  Stock options were granted on February 24, 2012, with 2,669 vested on February 24, 2016.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Shani Eli
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV, L3 6944020


EVP,Global Marketing&Portfolio

Signatures
/s/ Dov Bergwerk as attorney-in-fact for Eli Shani 8/19/2021
**Signature of Reporting Person Date
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Oct 2021 to Nov 2021 Click Here for more Teva Pharmaceutical Indu... Charts.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Nov 2020 to Nov 2021 Click Here for more Teva Pharmaceutical Indu... Charts.